Tezspire Approved: FDA approves maintenance treatment for severe asthma

Tezspire Approved: FDA approves maintenance treatment for severe asthma

Tezspire Approved: FDA approves maintenance treatment for severe asthma
What is asthmatic bronchitis?

It will be important to understand what does asthma mean, within the first place. Asthma means panting (breathlessness), in Greek. In reality, asthma is more then panting. for instance, if you exert yourself with intense exercise, you're feeling panting, but that's not asthma. Asthma means breathlessness thanks to the constriction of the respiratory tubes. The constriction of the big and tiny tubes of the lung could also be due to the spasm caused by certain factors, discussed separately on this page.

Let us briefly understand the structure and also the function of the lungs.

The lungs are two cone shaped vital organs on either side of the chest, as shown within the figure. Air, which we breathe through the nose, enters into the lungs through the air-tube (called Trachea) which bifurcates into two tubes, each visiting the respective lungs. Each of the bronchus (plural bronchi) branches into multiple, innumerous small tubes called bronchioles. The bronchioles cause terminal sacs called alveoli. The air eventually passses through the bronchioles to the alveoli to exchange CO2 (CO2) with Oxygen reciprocally.

In the normal circumstances, there's a transparent passage within the bronchi and therefore the bronchioles facilitating effortless breathing process. just in case of the asthmatic episode, because of certain factors the bronchi and also the bronchioles go in 'spasm' resulting in obstructed airway, not allowing the oxygen to travel across. this is often a typical phenomenon of the acute asthmatic episode.

So, asthmatic bronchitis is nothing but a disorder of the systema respiratorium whereby the lung tubes meet with episodic or chronic episodes of spasms, where the precipitating cause might differ from patient to patient and therefore the frequency of attacks, the duration of attack moreover because the intensity of the attack could vary from child to child.

The factors, which decide the intensity of the attack, don't seem to be only the external factors like the strength of the allergens or irritants but it's the individual sensitivity (susceptibility) which decides the intensity of the breathlessness. Similarly, the identical rules apply to frequency, the length of the attack. When said so, it's not difficult to derive that the kid Asthma could be a disorder where one must ascertain the 'internal' factors (such because the susceptibility of the patients) rather then just the external factors like the food allergens. This understanding is kind of vital with relevance the homeopathic approach to the treatment of asthma.

As a results of the complete process, which involves spasm and an inflammation of the lung tubules, the kid may present with cough, difficult breathing (called dyspnea), panting and weakness.

FDA approves maintenance treatment for severe asthma

Tezspire Approved: FDA approves maintenance treatment for severe asthma

Dec. 23, 2021-- FDA has approved Tezspire (tezepelumab-ekko) injection as an add-on maintenance treatment used to improve severe asthma symptoms when used with a patient’s current asthma medicine. Tezspire is approved for adults and children aged 12 years and older with severe asthma not controlled by their current asthma medicine. Tezspire is the first asthma treatment targeting thymic stromal lymphopoietin, a molecule involved in airway inflammation. Tezspire is also the first treatment for severe asthma that is not limited to a specific type of severe asthma.

Tezspire is administered once every four weeks by a health care professional through a subcutaneous (under the skin) injection.

Disease or Condition:

Asthma is a long-term inflammatory disease that causes the airways of the lungs to become swollen or inflamed and can be triggered by several factors, including allergen or irritant exposure and viral infections. An asthma attack (exacerbation) can include wheezing, cough, chest tightness, and make it hard to breathe.

Severe asthma attacks can be intense, last for long periods of time, and impact daily activities. Severe asthma symptoms usually do not get better with use of short-term treatments. Approximately 5-10 percent of Americans with asthma have severe asthma.


Safety and effectiveness of Tezspire were demonstrated in two clinical trials (NCT02054130 and NCT03347279), where participants with severe asthma received Tezspire 210 mg or placebo subcutaneously once every four weeks for 52 weeks.

Participants receiving Tezspire had significant reductions in the annualized rate of asthma attacks compared to placebo. Additionally, there were fewer asthma attacks requiring emergency room visits and/or hospitalization among participants treated with Tezspire compared to placebo. The benefits of Tezspire seen in participants weren’t limited by specific severe asthma type.

Safety Information:

Tezspire should not be used to treat short-term asthma symptoms or short-term asthma attacks. Patients should not discontinue systemic or inhaled corticosteroid treatments abruptly after starting therapy with Tezspire. Reductions in corticosteroid treatment dose, if appropriate, should be gradual and performed under the direct supervision of a health care professional. Patients with pre-existing helminth infections should be treated for the helminth infection before starting therapy with Tezspire for asthma. Patients with a serious hypersensitivity reaction to Tezspire must not take Tezspire. Live vaccines should be avoided in patients receiving Tezspire.

See the prescribing information for additional information on risks associated with Tezspire.


Tezspire received breakthrough designation for the treatment of severe asthma.